PL201666A1 - Sposob wytwarzania liposomow - Google Patents

Sposob wytwarzania liposomow

Info

Publication number
PL201666A1
PL201666A1 PL20166677A PL20166677A PL201666A1 PL 201666 A1 PL201666 A1 PL 201666A1 PL 20166677 A PL20166677 A PL 20166677A PL 20166677 A PL20166677 A PL 20166677A PL 201666 A1 PL201666 A1 PL 201666A1
Authority
PL
Poland
Prior art keywords
manufacturing liposomes
liposomes
manufacturing
Prior art date
Application number
PL20166677A
Other languages
English (en)
Inventor
Edgar Sache
Henri Bertrand
Original Assignee
Choay Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB44132/76A external-priority patent/GB1591306A/en
Application filed by Choay Sa filed Critical Choay Sa
Publication of PL201666A1 publication Critical patent/PL201666A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PL20166677A 1976-10-23 1977-10-22 Sposob wytwarzania liposomow PL201666A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB44132/76A GB1591306A (en) 1976-10-23 1976-10-23 Liposomes containing heparin and a process for obtaining them
GB3441077 1977-08-16

Publications (1)

Publication Number Publication Date
PL201666A1 true PL201666A1 (pl) 1979-04-09

Family

ID=26262280

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20166677A PL201666A1 (pl) 1976-10-23 1977-10-22 Sposob wytwarzania liposomow

Country Status (14)

Country Link
US (1) US4239754A (pl)
JP (1) JPS6055485B2 (pl)
AR (1) AR224100A1 (pl)
AU (1) AU519231B2 (pl)
DD (1) DD138881A5 (pl)
DE (1) DE2747378A1 (pl)
DK (1) DK470277A (pl)
ES (1) ES463427A1 (pl)
FR (1) FR2374910A1 (pl)
IE (1) IE45894B1 (pl)
LU (1) LU78361A1 (pl)
NL (1) NL7711610A (pl)
PL (1) PL201666A1 (pl)
SE (1) SE7711895L (pl)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7900458L (sv) * 1978-01-27 1979-07-28 Sandoz Ag Liposom-avgivningssystem for lekemedel
GB2026340B (en) * 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
JPS56120612A (en) * 1980-02-27 1981-09-22 Kanebo Keshohin Kk Beautifying cosmetic
US4820811A (en) * 1982-04-21 1989-04-11 Research Corporation Amine reacted therapeutic agents
US4451647A (en) * 1982-06-21 1984-05-29 Research Corporation Heparinized polyorganophosphazenes
US4542019A (en) * 1983-03-11 1985-09-17 John Lezdey Antacid compositions
DE3331009A1 (de) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
JPS60208910A (ja) * 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
FR2568774B2 (fr) * 1984-05-30 1989-05-19 Choay Sa Medicaments favorisant les proprietes d'ecoulement du sang et leur utilisation en therapeutique
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
US4923854A (en) * 1986-01-22 1990-05-08 The Liposome Company, Inc. Solubilization of hydrophobic materials using lysophospholipid
DE3614657A1 (de) * 1986-04-30 1987-11-05 Dornier Medizintechnik Pharmaka enthaltende lipidvesikel, verfahren zu ihrer herstellung und einbringung in den koerper eines lebewesens und freisetzung der in den lipidvesikeln enthaltende pharmaka
US4745105A (en) * 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US4745107A (en) * 1986-08-20 1988-05-17 Foley Kevin M Heparin derivatives with improved permeability
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5008242A (en) * 1986-12-24 1991-04-16 John Lezdey Treatment of inflammation using 1-antichymotrypsin
US4879282A (en) * 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
US4938965A (en) * 1987-07-22 1990-07-03 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Ocular delivery of prophylactic agents
US5464942A (en) * 1990-07-24 1995-11-07 Seikagaku Kogyo Kabushiki Kaisha Phospholipid- or lipid-linked glycosaminoglycan and process for producing the same
US5733892A (en) * 1990-07-24 1998-03-31 Seikagaku Corporation Metastasis inhibitor composition comprising a phospholipid-linked glycosaminoglycan and method for inhibiting metastasis employing the same
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
AR244546A1 (es) * 1990-10-30 1993-11-30 Gador Y Cia S A C I Lab Dr Procedimiento para la preparacion de liposomas de drogas insolubles en aceite en capsulas blandas de gelatina enterosolubles.
JP3199405B2 (ja) * 1991-08-30 2001-08-20 生化学工業株式会社 肝細胞球状集塊化剤及び球状集塊化肝細胞の製造方法
WO1995001163A1 (fr) * 1992-01-03 1995-01-12 Corbiere Jerome Nouvelles preparations pharmaceutiques a base de peptides pour la voie generale
FR2685868B1 (fr) * 1992-01-03 1995-06-23 Corbiere Jerome Nouvelles preparations pharmaceutiques a base de peptides pour la voie generale.
US6916489B2 (en) * 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
US5342621A (en) * 1992-09-15 1994-08-30 Advanced Cardiovascular Systems, Inc. Antithrombogenic surface
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5643957A (en) * 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US20010003001A1 (en) * 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DE4313402A1 (de) * 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermale Wirkstoffzubereitung
AU6785094A (en) * 1993-05-07 1994-12-12 Sequus Pharmaceuticals, Inc. Subcutaneous liposome delivery method
US5989539A (en) * 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6090958A (en) * 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1151836C (zh) * 1995-03-31 2004-06-02 艾米斯菲尔技术有限公司 用作传送活性剂的化合物和组合物
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
WO1997010197A1 (en) * 1995-09-11 1997-03-20 Emisphere Technologies, Inc. METHOD FOR PREPARING φ-AMINOALKANOIC ACID DERIVATIVES FROM CYCLOALKANONES
AU2595697A (en) 1996-03-29 1997-10-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1997047288A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
IE960485A1 (en) * 1996-07-02 1998-01-14 Univ Dublin Organised assemblies containing entrapped negatively charged¹polyelectrolytes
WO1998021951A1 (en) 1996-11-18 1998-05-28 Emisphere Technologies, Inc. Methods and compositions for inducing oral tolerance in mammals
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) * 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE383169T1 (de) 1997-02-07 2008-01-15 Emisphere Tech Inc Komponente und zusammensetzungen zur verabreichung von wirkstoffen
US5804688A (en) * 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5863944A (en) * 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) * 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
EP1059941B1 (en) * 1998-03-05 2004-05-26 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use
KR100314496B1 (ko) 1998-05-28 2001-11-22 윤동진 항혈전성이 있는 헤파린 유도체, 그의 제조방법 및 용도
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6908900B2 (en) * 2001-01-17 2005-06-21 Zimmer & Associates Ag Compositions and methods for enhanced pharmacological activity through oral and parenteral administration of compositions comprising polypeptide drug substances and other poorly absorbed active ingredients
US20030060413A1 (en) * 2001-09-06 2003-03-27 Zimmer Robert H. Derivatives of pseudo-peptides, their preparation and their biological uses
US7671029B2 (en) 1999-08-06 2010-03-02 Immupharma Sa Compositions and methods for enhanced pharmacological activity of compositions comprising peptide drug substances
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
EP1237872B1 (en) 1999-12-16 2008-02-27 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6489311B1 (en) * 2000-05-02 2002-12-03 Charlotte-Mecklenburg Hospital Authoirty Method for the prevention of apoptosis
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
JP2004535434A (ja) * 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
EP1423081A4 (en) * 2001-06-25 2005-05-25 Depuy Int Ltd COMPOSITION WITH GLYCOSAMINOGYCANES AND HYALURONIDASE INHIBITORS FOR THE TREATMENT OF ARTHRITIC JOINTS
BRPI0214168B8 (pt) 2001-11-14 2021-05-25 Centocor Inc anticorpos anti-il-6, moléculas de ácido nucleico codificando os mesmos, vetores compreendendo as referidas moléculas, composições e formulações compreendendo os referidos anticorpos, bem como métodos de produção dos mesmos
US20030180348A1 (en) * 2002-03-22 2003-09-25 Levinson R. Saul Transcellular drug delivery system
AU2003230985A1 (en) * 2002-04-18 2003-11-03 Stephen H. Embury Method and composition for preventing pain in sickle cell patients
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
US6702850B1 (en) 2002-09-30 2004-03-09 Mediplex Corporation Korea Multi-coated drug-eluting stent for antithrombosis and antirestenosis
JP4463109B2 (ja) * 2002-11-07 2010-05-12 アドバンスド バイオニュートリション コーポレーション 栄養補助食品および水生動物の給餌方法
EP1623011B1 (en) 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
EP1658273B1 (en) * 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
ES2286679T3 (es) * 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
UA89481C2 (uk) 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
JP2005209106A (ja) * 2004-01-26 2005-08-04 Nec Corp 携帯通信端末、受信メール管理方法、プログラムおよび記録媒体
US7252446B2 (en) * 2004-03-31 2007-08-07 Brother Kogoy Kabushiki Kaisha Image forming apparatus
EP1750754A4 (en) * 2004-03-31 2010-09-22 Centocor Ortho Biotech Inc HUMAN GLP-1 MIMETIC BODIES, COMPOSITIONS, METHODS AND USES
US7393662B2 (en) 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
CA2613818C (en) 2005-06-30 2013-08-27 Centocor, Inc. Anti-il-23 antibodies, compositions, methods and uses
US20070021378A1 (en) * 2005-07-22 2007-01-25 The Regents Of The University Of California Heparin compositions and selectin inhibition
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
AR064623A1 (es) * 2006-12-21 2009-04-15 Centocor Inc Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
US20100021538A1 (en) * 2008-02-29 2010-01-28 Youngro Byun Pharmaceutical compositions containing heparin derivatives
MX2011001409A (es) 2008-08-14 2011-03-29 Cephalon Australia Pty Ltd Anticuerpos anti-il-12/il-23.
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
NZ603581A (en) 2010-06-19 2015-05-29 Sloan Kettering Inst Cancer Anti-gd2 antibodies
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
RU2014132761A (ru) 2012-02-21 2016-04-10 Эдванст Бионутришн Корпорейшн Композиции и способы целевой доставки биологически активного агента водным организмам
BR112014028094B1 (pt) 2012-05-09 2022-03-03 Cantex Pharmaceuticals, Inc Uso de um heparinoide interagindo com fator de plaqueta 4
US20140255403A1 (en) 2013-03-06 2014-09-11 Hadasit Medical Research Services & Development Ltd. Oral composition comprising a tnf antagonist and use thereof
AU2014228772B2 (en) 2013-03-15 2019-02-28 Memorial Sloan Kettering Cancer Center High affinity anti-GD2 antibodies
US8962836B2 (en) 2013-03-15 2015-02-24 Mannkind Corporation Formation of N-protected bis-3,6-(4-aminobutyl)-2,5-diketopiperazine through a cyclic alpha-N-protected amino ester
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
KR102618312B1 (ko) 2015-03-17 2023-12-28 메모리얼 슬로안 케터링 캔서 센터 항muc16 항체 및 그의 용도
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
BR112019000683A2 (pt) 2016-07-15 2019-04-24 Poseida Therapeutics Inc receptores de antígeno quiméricos e métodos para uso
WO2018014039A1 (en) 2016-07-15 2018-01-18 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
JP6409837B2 (ja) * 2016-09-08 2018-10-24 トヨタ自動車株式会社 回転電機ロータ及び回転電機ロータの製造方法
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3574012A1 (en) 2017-01-27 2019-12-04 Memorial Sloan Kettering Cancer Center Bispecific her2 and cd3 binding molecules
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
KR20240038148A (ko) 2017-02-07 2024-03-22 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
AU2018393110B2 (en) 2017-12-20 2023-04-27 Poseida Therapeutics, Inc. VCAR compositions and methods for use
JP7539834B2 (ja) 2018-02-01 2024-08-26 メモリアル スローン ケタリング キャンサー センター ガレクチン－３に対する抗体及びその使用方法
JP2021523138A (ja) 2018-05-11 2021-09-02 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ−２３抗体を使用してうつを治療する方法
EP3824296B1 (en) 2018-07-20 2026-04-01 Lipocine Inc. Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases
EP3898993A1 (en) 2018-12-20 2021-10-27 Poseida Therapeutics, Inc. Nanotransposon compositions and methods of use
US20220153827A1 (en) 2019-01-15 2022-05-19 Janssen Biotech, Inc. Anti-TNF Antibody Compositions and Methods for the Treatment of Juvenile Idiopathic Arthritis
KR20210118878A (ko) 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
EP3938390A1 (en) 2019-03-14 2022-01-19 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
CN113840837A (zh) 2019-03-14 2021-12-24 詹森生物科技公司 用于产生抗tnf抗体组合物的方法
EP3972690A4 (en) 2019-05-23 2023-07-05 Janssen Biotech, Inc. METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA
JP2022536279A (ja) 2019-06-03 2022-08-15 ヤンセン バイオテツク，インコーポレーテツド 乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
MA56026A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
WO2021046261A1 (en) 2019-09-05 2021-03-11 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
CN115135672A (zh) 2019-12-20 2022-09-30 波赛达治疗公司 抗muc1组合物和使用方法
CN115515646A (zh) 2020-03-04 2022-12-23 波赛达治疗公司 用于治疗代谢性肝病的组合物和方法
US20230121433A1 (en) 2020-03-11 2023-04-20 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
US20230190811A1 (en) 2020-04-14 2023-06-22 Poseida Therapeutics, Inc. Compositions and methods for use in the treatment of cancer
WO2021214588A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating coronavirus infections
WO2021214587A1 (en) 2020-04-21 2021-10-28 Janssen Biotech, Inc. Anti-tnf alpha agent for treating viral infections
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
EP4298205A1 (en) 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Genetically modified induced pluripotent stem cells and methods of use thereof
EP4301863A1 (en) 2021-03-04 2024-01-10 Poseida Therapeutics, Inc. Compositions and methods for the treatment of hemophilia
IL309996A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
IL309997A (en) 2021-07-09 2024-03-01 Janssen Biotech Inc Production methods for the production of anti-TNF antibody compositions
AU2022360244A1 (en) 2021-10-04 2024-04-11 Poseida Therapeutics, Inc. Transposon compositions and methods of use thereof
WO2023164573A1 (en) 2022-02-23 2023-08-31 Poseida Therapeutics, Inc. Genetically modified cells and methods of use thereof
JP2025528163A (ja) 2022-08-11 2025-08-26 ポセイダ セラピューティクス，インコーポレイティド キメラｃｄ８－アルファ補助受容体組成物及び使用方法
AU2024226443A1 (en) 2023-02-21 2025-08-28 Demeetra Agbio, Inc. Compositions and methods for genome editing
CN121079405A (zh) 2023-02-21 2025-12-05 波西达治疗公司 用于基因组编辑的组合物和方法
KR20250155027A (ko) 2023-02-21 2025-10-29 포세이다 테라퓨틱스, 인크. Aav piggybac 트랜스포존 폴리뉴클레오티드 조성물 및 이의 사용 방법
IL327036A (en) 2023-09-19 2026-05-01 Poseida Therapeutics Inc Compositions and methods for combining viral vectors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2055083A (en) * 1932-07-13 1936-09-22 Winthrop Chem Co Inc Pharmaceutical preparation
US3395222A (en) * 1966-03-11 1968-07-30 Armour Pharma Prolongation of clotting time of blood
GB1502774A (en) * 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations

Also Published As

Publication number Publication date
DD138881A5 (de) 1979-11-28
IE45894L (en) 1978-04-23
AR224100A1 (es) 1981-10-30
US4239754A (en) 1980-12-16
IE45894B1 (en) 1982-12-29
DK470277A (da) 1978-04-24
SE7711895L (sv) 1978-04-24
LU78361A1 (fr) 1979-06-01
JPS6055485B2 (ja) 1985-12-05
AU2993777A (en) 1979-04-26
NL7711610A (nl) 1978-04-25
ES463427A1 (es) 1979-06-01
AU519231B2 (en) 1981-11-19
FR2374910A1 (fr) 1978-07-21
JPS53133616A (en) 1978-11-21
FR2374910B1 (pl) 1981-07-10
DE2747378A1 (de) 1978-04-27

Similar Documents

Publication Publication Date Title
PL199748A1 (pl) Sposob selektywnego wytwarzania p-dwualkilobenzenow
PL196505A1 (pl) Sposob wytwarzania nowych zwiazkow aminoalkiloheterocyklicznych
PL201286A1 (pl) Sposob wytwarzania nowych 1-aryloksy-2-hydroksy-3-alkileno-aminopropanow
PL195088A1 (pl) Sposob wytwarzania n-fosfonometyloglicyny
NL7711610A (nl) Heparine bevattende liposomen en werkwijze ter bereiding ervan.
PL200289A1 (pl) Sposob wytwarzania zwiazkow 3-chlorocefemowych
PL201837A1 (pl) Sposob wytwarzania zwiazkow cynoorganicznych
PL215007A1 (pl) Sposob wytwarzania gamma-pironow
PL199298A1 (pl) Sposob wytwarzania 2-bromo-6-fluoro-n-2-imidazolidynylideno-benzaminy
PL196820A1 (pl) Sposob wytwarzania zwiazkow 3-chlorowcometylocefemowych-3
PL200534A1 (pl) Sposob wytwarzania nowych oksadeztiacefalosporyn
PL199633A1 (pl) Sposob wytwarzania 5-m-toliloksyuracylu
PL199364A1 (pl) Sposob wytwarzania nowych pochodnych benzoksycyny
PL201885A1 (pl) Sposob wytwarzania 4a-arylo-osmiowodoro-1h-2-piryndyn
PL202091A1 (pl) Sposob wytwarzania gamma-pyronow
PL201839A1 (pl) Sposob wytwarzania zwiazkow cynoorganicznych
PL201133A1 (pl) Sposob wytwarzania nowych pirydobenzodwuazepinonow
PL202402A1 (pl) Sposob wytwarzania kwasu 6-aminopenicylanowego
PL201332A1 (pl) Sposob wytwarzania kompozycji cynk-bacytracyna
PL195267A1 (pl) Sposob wytwarzania(2-ketopirolidyno)-alkanokarbonamidow
PL202935A1 (pl) Sposob wytwarzania estrow
PL202697A1 (pl) Sposob wytwarzania 2-bromo-alfa-ergokryptyny
PL197311A1 (pl) Sposob wytwarzania nowych zwiazkow ketotia
IT1081020B (it) Metodo di fabbricazione di aspidospermidine
PL192043A1 (pl) Sposob wytwarzania polinitrozwiazkow